

22 January 2018

PainChek Limited (**ASX: PCK**)
ABN 21 146 035 127
Suite 401, 35 Lime Street, Sydney, NSW, 2000
Registered Office: Suite 5, 95 Hay Street Subiaco WA 6008
Phone +61 8 9388 8290
info@paincheck.com

PainChek™ Head of Business Development ANZ appointment

PainChek Ltd confirms the appointment of David Allsopp as Head of Business Development Australia and New Zealand commencing 22nd January 2018 and based in Sydney NSW.

David has ten years' experience in the Australia and New Zealand aged care and allied healthcare sectors having worked for Healthstrong and Mirus Australia in senior Business Development roles. In both instances David has been instrumental in the successful growth of these businesses and has, in the process, built high-level customer relationships within these sectors.

"We are delighted to welcome David to the PainChek team. David has the experience, knowledge and capabilities required to lead PainChek's business development in Australia and New Zealand" said Philip Daffas CEO and Managing Director PainChek Ltd.

"Moreover David is passionate about the aged care and allied health market and shares our passion as to how the PainChek App can help carers transform pain assessment and overall residential care" added Daffas.


For further information contact:

Ian Hobson
Company Secretary
Tel: +61 8 9388 8290


Philip Daffas
Managing Director
Tel: +61 406-537-235

The PainChek™ Technology:

PainChek™ uses cameras in smartphones and tablets to capture a brief video of the person, which is analysed in real time using facial recognition software to detect the presence of facial micro- expressions that are indicative of the presence of pain.



PainChek™ artificial intelligence assesses facial micro-expressions that are indicative of the presence of pain



PainChek™ six domains of pain assessment that calculates pain severity score

This data is then combined with other indicators of pain, such as vocalisations, behaviours and movements captured to calculate a pain severity score. Due to its speed, ease of use and it's reproducibility, PainChek™ will be able to be used to detect and measure a person's pain, and then further measurements can be used to monitor the effectiveness of pain management.

PainChek™ will be rolled out globally in two phases: first, PainChek™ which is designed for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek™ for Children who have not yet learnt to speak.